{"id":152958,"date":"2026-11-14T20:00:01","date_gmt":"2026-11-14T11:00:01","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/3750-20261113-01_wp_financial_summary\/"},"modified":"2026-11-14T20:00:01","modified_gmt":"2026-11-14T11:00:01","slug":"3750-20261113-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/","title":{"rendered":"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)"},"content":{"rendered":"<p>Due to establishment of domestic mass-production systems and the full-scale commercial launch of the Celuration centrifuge and Celuration cell therapy kits, interim sales for the fiscal year ending March 2027 increased to 66 million yen, up 262.7% year-over-year. Operating loss was 311 million yen, and interim net loss attributable to owners of parent was 224 million yen. Full-year earnings guidance is maintained, and the start of insurance coverage for the cell therapy kits is expected to contribute to future performance. Financial condition remains at risk of insolvency, with material uncertainty regarding the assumption of going concern. Measures including domestic production progress, expansion into new fields, and cost reductions are being implemented.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3750","jir_company_name":"ADR Biomedical Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/3750-20261113-01.pdf","jir_short_summary":"Due to establishment of domestic mass-production systems and the full-scale commercial launch of the Celuration centrifuge and Celuration cell therapy kits, interim sales for the fiscal year ending March 2027 increased to 66 million yen, up 262.7% year-over-year. Operating loss was 311 million yen, and interim net loss attributable to owners of parent was 224 million yen. Full-year earnings guidance is maintained, and the start of insurance coverage for the cell therapy kits is expected to contribute to future performance. Financial condition remains at risk of insolvency, with material uncertainty regarding the assumption of going concern. Measures including domestic production progress, expansion into new fields, and cost reductions are being implemented.","jir_summary":"### Overview of Performance\nInterim net sales rose substantially to 66 million yen (up 262.7% year-over-year), while operating loss remained at 311 million yen and ordinary loss at 315 million yen, keeping the company in a deficit position. Full-scale commercial sales of the newly launched Celuration cell therapy kits are expected to contribute from the second half of fiscal 2027, and progress is being made in establishing domestic mass-production systems for key products. The full-year forecast is unchanged, but material uncertainty regarding the assumption of going concern is disclosed.\n\n### Financial Position and Capital Policy\nThe financial position shows total assets of 272 million yen and net assets of -202 million yen, indicating continued negative net assets; current liabilities amount to 463 million yen, driven in part by increased short-term borrowings. As of November 13, 2026, measures to stabilize cash flow were decided, including HG Capital's debt waiver of 400 million yen and maintenance of a commitment line up to 500 million yen as financial support. Material uncertainty regarding the assumption of going concern continues to be disclosed.","jir_financial_highlights":"Net Sales: 66 million yen (Up 262.7% year-over-year)\nOperating Income: -311 million yen (Year-over-year comparison unknown (prior period: -332 million yen))\nOrdinary Income: -315 million yen (Year-over-year comparison unknown (prior period: -347 million yen))\nNet Income Attributable to Owners of Parent (Interim): -224 million yen (Year-over-year comparison unknown (prior period: -131 million yen))\nTotal Assets: 272 million yen (Decrease of -95 million yen from the end of the previous consolidated fiscal year)\nEquity Ratio: 6.0% (Decrease from the end of the previous consolidated fiscal year)","jir_category":"","jir_hashtags":"#ADRBiomedicalHoldings, #Earnings, #FinancialCondition, #CelurationCellTherapyKit","jir_key_figures":"Net Sales: 66 million yen (Up 262.7% year-over-year)\nInterim Net Loss Attributable to Owners of Parent: -224 million yen\nTotal Assets: 272 million yen\nEquity Ratio: 6.0%\nShort-term Borrowings: 370,000 yen","jir_meta_title":"ADR Biomedical Holdings Inc. - Financial Summary for Q2 FY2027 | Commercial Launch and Financial Instability","jir_meta_description":"Financial summary for ADR Biomedical Holdings Inc. for the second quarter of fiscal 2027: sales of 66 million yen (+262.7%) despite continued net losses. Coverage of the commercial launch of Celuration cell therapy kits, progress on domestic production, details of financial support, and material uncertainty about going concern.","jir_og_title":"ADR Biomedical Holdings Inc. | Financial Summary for Q2 FY2027","jir_og_description":"Net sales rose sharply to 66 million yen, but net losses persist. The company aims to improve its financial profile through expanded sales of Celuration products, domestic production, and financial support measures, while noting material uncertainty about going concern.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59367,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-152958","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/\",\"name\":\"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-14T11:00:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/","name":"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-14T11:00:01+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261113-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59367","title":"ADR120S INC","ticker":"3750"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/152958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=152958"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/152958\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=152958"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=152958"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=152958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}